Introduction: The DrillCutTM morcellator is marketed for its fast and highly efficient removal of prostatic tissue and a higher level of patient safety. However, a paucity of publications has looked into its actual efficacy and safety. The aim of our study was to evaluate its ex vivo and in vivo efficiency and to compare its results with other devices presented in the literature. Patients and Methods: We conducted a prospective pilot study on patients who underwent holmium laser enucleation of the prostate (HoLEP) from 2017 to 2018 using the Top-Down technique. Enucleated adenomas were morcellated using the DrillCutTM morcellator. We collected both preoperative and operative data. Operative data included the enucleated adenoma weight and operative time. Various morcellator parameters were collected including morcellation time and efficiency. We recorded the encountered complications and device malfunction. Ex vivo characteristics were evaluated in terms of morcellation speed and aspiration power. Results: Sixty consecutive patients with a median age of 72.8 years were included. The enucleated adenoma was retrieved in 12.5 min (4–58). The median resected prostatic weight was 90 g (44–242). The DrillCutTM efficiency was calculated as 6.46 g/min (2.7–15). Only one patient had a simple bladder mucosal injury. Device malfunction was encountered in 4 patients (6.6%) due to blockage of the morcellator blades. The ex vivo aspiration speed was 52 s/L, while the morcellation power was 14 g/2 min. Conclusion: Our results showed that the DrillCut morcellator was effective and safe in managing our patients post-HoLEP. The DrillCutTM has better ex vivo morcellation power but modest aspiration speed in comparison to other morcellators.

Keywords:
Laser, Prostate enucleation, Morecellation
1.
Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy.
Eur Urol
. 2006 Jan; 49(1): 87–91.
2.
Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G. A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia.
J Urol
. 2004 May; 171(5): 1773–81.
3.
van Rij S, Gilling PJ. In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new ‘gold standard’.
Curr Urol Rep
. 2012 Dec; 13(6): 427–32.
4.
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.
Eur Urol
. 2010 Sep; 58(3): 384–97.
5.
Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline.
J Urol
. 2018 Sep; 200(3): 612–9.
6.
Gravas S, Bach T, Drake M, et al. EAU guidelines on non-neurogenic male LUTS including benign prostatic obstruction. 2017.
7.
Dusing MW, Krambeck AE, Terry C, Matlaga BR, Miller NL, Humphreys MR, et al. Holmium laser enucleation of the prostate: efficiency gained by experience and operative technique.
J Urol
. 2010 Aug; 184(2): 635–40.
8.
Cornu JN, Terrasa JB, Lukacs B. Ex vivo comparison of available morcellation devices during holmium laser enucleation of the prostate through objective parameters.
J Endourol
. 2014 Oct; 28(10): 1237–40.
9.
Becker B, Netsch C, Glybochko P, Rapoport L, Taratkin M, Enikeev D. A Feasibility Study Utilizing the Thulium and Holmium Laser in Patients for the Treatment of Recurrent Benign Prostatic Hyperplasia after Previous Prostatic Surgery.
Urol Int
. 2018; 101(2): 212–8.
10.
Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.
Can Urol Assoc J
. 2018 Oct; 12(10): 303–12.
11.
McAdams S, Nunez-Nateras R, Martin CJ, Cha S, Humphreys MR. Morcellation Efficiency in Holmium Laser Enucleation of the Prostate: Oscillating Morcellator Outperforms Reciprocating Morcellator With no Apparent Learning Curve.
Urology
. 2017 Aug; 106: 173–7.
12.
Elshal AM, Mekkawy R, Laymon M, El-Assmy A, El-Nahas AR. Towards optimizing prostate tissue retrieval following holmium laser enucleation of the prostate (HoLEP): assessment of two morcellators and review of literature.
Can Urol Assoc J
. 2015 Sep-Oct; 9(9-10):E618–25.
13.
Ibrahim A, Elhilali MM, Elkoushy MA, Andonian S, Carrier S. DrillCutTM vs VersaCutTM prostate tissue morcellation devices after holmium laser enucleation: A prospective, randomized controlled trial.
Can Urol Assoc J
. 2018 Dec; 13(8).
14.
El Tayeb MM, Borofsky MS, Paonessa JE, Lingeman JE. Wolf Piranha Versus Lumenis VersaCut Prostate Morcellation Devices: A Prospective Randomized Trial.
J Urol
. 2016 Feb; 195(2): 413–7.
15.
Rivera ME, Lingeman JE, Heinsimer K, York NE, Krambeck AE. A Survey of Morcellator Preference and Cost Comparison of the Lumenis VersaCut and Wolf Piranha Morcellators.
Urology
. 2018 Jan; 111: 54–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.